TSX:LABS - CA58504D1006 - Common Stock
The current stock price of LABS.CA is 0.08 CAD. In the past month the price increased by 14.29%. In the past year, price increased by 14.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
WEED-DB.CA | CANOPY GROWTH CORP | N/A | 20.59B | ||
BHC.CA | BAUSCH HEALTH COS INC | 1.95 | 3.76B | ||
TLRY.CA | TILRAY BRANDS INC | N/A | 2.08B | ||
CRON.CA | CRONOS GROUP INC | 50.86 | 1.36B | ||
DHT-UN.CA | DRI HEALTHCARE TRUST | 6.59 | 784.17M | ||
WEED.CA | CANOPY GROWTH CORP | N/A | 657.29M | ||
GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 647.73M | ||
TSND.CA | TERRASCEND CORP | N/A | 580.48M | ||
DHT-U.CA | DRI HEALTHCARE TRUST | 4.7 | 559.49M | ||
ACB.CA | AURORA CANNABIS INC | N/A | 416.25M | ||
CPH.CA | CIPHER PHARMACEUTICALS INC | 25.29 | 404.46M | ||
HITI.CA | HIGH TIDE INC | N/A | 401.13M |
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
MEDIPHARM LABS CORP
151 John Street
Barrie ONTARIO L4N 2L1 CA
CEO: Patrick McCutcheon
Employees: 161
Phone: 17057197425
The current stock price of LABS.CA is 0.08 CAD. The price increased by 6.67% in the last trading session.
The exchange symbol of MEDIPHARM LABS CORP is LABS and it is listed on the Toronto Stock Exchange exchange.
LABS.CA stock is listed on the Toronto Stock Exchange exchange.
MEDIPHARM LABS CORP (LABS.CA) has a market capitalization of 33.66M CAD. This makes LABS.CA a Nano Cap stock.
MEDIPHARM LABS CORP (LABS.CA) currently has 161 employees.
MEDIPHARM LABS CORP (LABS.CA) has a support level at 0.07 and a resistance level at 0.09. Check the full technical report for a detailed analysis of LABS.CA support and resistance levels.
The Revenue of MEDIPHARM LABS CORP (LABS.CA) is expected to grow by 13.37% in the next year. Check the estimates tab for more information on the LABS.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LABS.CA does not pay a dividend.
MEDIPHARM LABS CORP (LABS.CA) will report earnings on 2025-11-12.
MEDIPHARM LABS CORP (LABS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
ChartMill assigns a technical rating of 4 / 10 to LABS.CA. When comparing the yearly performance of all stocks, LABS.CA turns out to be only a medium performer in the overall market: it outperformed 54.46% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to LABS.CA. While LABS.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months LABS.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 22.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.56% | ||
ROE | -21.74% | ||
Debt/Equity | 0.01 |
For the next year, analysts expect an EPS growth of 61.75% and a revenue growth 13.37% for LABS.CA